Trial reportAnnals of the rheumatic diseases2023
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis.
Trial report in Annals of the rheumatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02374021 (Treatments Against RA and Effect on FDG-PET/CT), which is not on this map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Who cites it
43 citing papers in PubMed, 65 citations in OpenAlex.
- Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial.American heart journal · 2026Trial
- The efficacy and safety of hydroxychloroquine in patients with chronic inflammatory cardiomyopathy: a multicenter randomized study (HYPIC trial).BMC medicine · 2025Trial
- Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial.Arthritis research & therapy · 2024Trial
- Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial.Journal of the American Heart Association · 2024Trial
- Temporal Trends and Short- and Long-Term Mortality of People With Acute Myocardial Infarction and Rheumatoid Arthritis: A Nationwide Cohort Study.Arthritis care & research · 2026Article
- The evolving comorbidity landscape of rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Position Statement on Multimodal Cardiac Imaging in Patients with Systemic Diseases - 2026.Arquivos brasileiros de cardiologia · 2026Article
- Article
- Observational
- Review
- Lipid changes after interleukin-6 blockade in rheumatoid arthritis: beyond cholesterol elevation toward hepatic inflammatory-lipoprotein remodeling.Frontiers in cardiovascular medicine · 2026Review
- Lipid metabolism at the intersection of rheumatoid arthritis and atherosclerosis.Frontiers in immunology · 2026Review
- High-sensitivity C-reactive protein is associated with altered cardiac structure and function in psoriasis: The PSOCADIA study.International journal of cardiology. Heart & vasculature · 2025Article
- Beyond Conventional Imaging: Nuclear Imaging in Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
- Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.Journal of clinical pharmacology · 2025Article
- Early prediction and warning of MODS following major trauma via identification of cytokine storm: A prospective cohort study.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2025Article
- Metabolic Consequences of Rheumatoid Arthritis.Arthritis care & research · 2025Review
- Rationale and design of the rheumatoid arthritis non-responders to treatment (RANT) study: Use of a bioinformatics platform and "decentralized" clinical recruitment design.Contemporary clinical trials · 2025Article
- No association between vascular inflammation and estimated glomerular filtration rate in patients with rheumatoid arthritis: secondary analysis of the TARGET trial.Scandinavian journal of rheumatology · 2025Article
- The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations.Rheumatology and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveRecent large-scale randomised trials demonstrate that immunomodulators reduce cardiovascular (CV) events among the general population. However, it is uncertain whether these effects apply to rheumatoid arthritis (RA) and if certain treatment strategies in RA reduce CV risk to a greater extent.
methodsPatients with active RA despite use of methotrexate were randomly assigned to addition of a tumour necrosis factor (TNF) inhibitor (TNFi) or addition of sulfasalazine and hydroxychloroquine (triple therapy) for 24 weeks. Baseline and follow-up
results115 patients completed the protocol. The two treatment groups were well balanced with a median age of 58 years, 71% women, 57% seropositive and a baseline disease activity score in 28 joints of 4.8 (IQR 4.0, 5.6). Baseline TBR was similar across the two groups. Significant TBR reductions were observed in both groups-ΔTNFi: -0.24 (SD=0.51), Δtriple therapy: -0.19 (SD=0.51)-without difference between groups (difference in Δs: -0.02, 95% CI -0.19 to 0.15, p=0.79). While disease activity was significantly reduced across both treatment groups, there was no association with change in TBR (β=0.04, 95% CI -0.03 to 0.10).
conclusionWe found that addition of either a TNFi or triple therapy resulted in clinically important improvements in vascular inflammation. However, the addition of a TNFi did not reduce arterial inflammation more than triple therapy. TRIAL REGISTRATION NUMBER: NCT02374021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.